N/A
N=459
A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
Migraine Disorders · Headache
Bottom Line
View on ClinicalTrials.gov: NCT01946126 ↗Enrolled (actual)
459
Serious AEs
—
Results posted
Mar 2016
Primary outcome: Primary: Presence or Absence of Prophylactic Medication for Headache/Migraine — 166; 227; 18; 48 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- No Intervention (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Allergan
- Primary completion
- Apr 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Presence or Absence of Prophylactic Medication for Headache/Migraine |
166; 227; 18; 48 | — |
| SECONDARY Number of Unique Prophylactic Medications for Headache/Migraine Reported |
2.7; 1.8 | — |
| SECONDARY Number of Days With a Headache Recorded at the Visit With the Highest Number of Headaches |
22.0; 19.2 | — |
| SECONDARY Highest Number of Headache Days Per Month at a Qualifying Visit |
16.28; 14.01 | — |
| SECONDARY Number of Visits for Headache Diagnosis |
4.7; 3.5 | — |
Summary
This study is a retrospective chart review in patients diagnosed with headache or migraine to evaluate treatment patterns and diagnosis.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of chronic migraine or other diagnosis of migraine or headache for a minimum of 15 months
- Eight (8) headache days per month for at least 1 of the preceding 15 months
Exclusion Criteria
- Not currently diagnosed with chronic migraine, headache or migraine
- History of receiving botulinum toxin injections for the treatment of chronic migraine.
Data sourced from ClinicalTrials.gov (NCT01946126). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.